Satheesh Chonat

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5224021/publications.pdf

Version: 2024-02-01

68	1,055	394421	454955
papers	citations	19 h-index	30 g-index

73	73	73	868
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood, 2018, 131, 2183-2192.	1.4	121
2	Genotype-phenotype correlations in hereditary elliptocytosis and hereditary pyropoikilocytosis. Blood Cells, Molecules, and Diseases, 2016, 61, 4-9.	1.4	60
3	Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease. Haematologica, 2018, 103, e483-e485.	3.5	60
4	Extracellular fluid tonicity impacts sickle red blood cell deformability and adhesion. Blood, 2017, 130, 2654-2663.	1.4	47
5	Genotypeâ€phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, 472-482.	4.1	47
6	Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica, 2019, 104, e51-e53.	3.5	46
7	Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal. Haematologica, 2020, 105, 539-544.	3.5	44
8	Mitapivat versus Placebo for Pyruvate Kinase Deficiency. New England Journal of Medicine, 2022, 386, 1432-1442.	27.0	42
9	Use of premedication for intubation in tertiary neonatal units in the United Kingdom. Paediatric Anaesthesia, 2009, 19, 653-658.	1.1	41
10	Complement serves as a switch between CD4+ T cellâ€“independent and â€“dependent RBC antibody responses. JCI Insight, 2018, 3, .	5.0	40
11	Recipient priming to one RBC alloantigen directly enhances subsequent alloimmunization in mice. Blood Advances, 2018, 2, 105-115.	5.2	36
12	Marginal zone B cells mediate a CD4 T-cellâ€“dependent extrafollicular antibody response following RBC transfusion in mice. Blood, 2021, 138, 706-721.	1.4	34
13	The Spectrum of SPTA1-Associated Hereditary Spherocytosis. Frontiers in Physiology, 2019, 10, 815.	2.8	32
14	Marginal Zone B Cells Induce Alloantibody Formation Following RBC Transfusion. Frontiers in Immunology, 2018, 9, 2516.	4.8	31
15	Current Standards of Care and Long Term Outcomes for Thalassemia and Sickle Cell Disease. Advances in Experimental Medicine and Biology, 2017, 1013, 59-87.	1.6	26
16	Molecular and phenotypic diversity of <I>CBL</I>-mutated juvenile myelomonocytic leukemia. Haematologica, 2022, 107, 178-186.	3.5	25
17	Examining the Role of Complement in Predicting, Preventing, and Treating Hemolytic Transfusion Reactions. Transfusion Medicine Reviews, 2019, 33, 217-224.	2.0	23
18	Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease. Haematologica, 2020, 105, 2887-2891.	3.5	22

#	Article	IF	Citations
19	Challenges in the treatment and prevention of delayed hemolytic transfusion reactions with hyperhemolysis in sickle cell disease patients. Transfusion, 2019, 59, 1698-1705.	1.6	19
20	Comorbidities and complications in adults with pyruvate kinase deficiency. European Journal of Haematology, 2021, 106, 484-492.	2.2	17
21	Are We Forgetting About IgA? A Reâ€examination of Coronavirus Disease 2019 Convalescent Plasma. Transfusion, 2021, 61, 1740-1748.	1.6	16
22	Role of complement in alloimmunization and hyperhemolysis. Current Opinion in Hematology, 2020, 27, 406-414.	2.5	15
23	The pyruvate kinase (PK) to hexokinase enzyme activity ratio andÂerythrocyte PK protein level in the diagnosis and phenotype of PK deficiency. British Journal of Haematology, 2021, 192, 1092-1096.	2.5	15
24	Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab. British Journal of Haematology, 2016, 175, 744-747.	2.5	14
25	Challenges in preventing and treating hemolytic complications associated with red blood cell transfusion. Transfusion Clinique Et Biologique, 2019, 26, 130-134.	0.4	14
26	T-follicular helper cell expansion and chronic T-cell activation are characteristic immune anomalies in Evans syndrome. Blood, 2022, 139, 369-383.	1.4	14
27	Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency. Blood Advances, 2022, 6, 1844-1853.	5.2	12
28	Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation. Frontiers in Immunology, 2020, 11, 905.	4.8	11
29	T Cell-Epstein-Barr Virusâ€“Associated Hemophagocytic Lymphohistiocytosis (HLH) Occurs in Non-Asians and Is Associated with a T Cell Activation State that Is Comparable to Primary HLH. Journal of Clinical Immunology, 2021, 41, 1582-1596.	3.8	11
30	Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice. Blood Advances, 2021, 5, 527-538.	5.2	11
31	Pyruvate kinase deficiency in children. Pediatric Blood and Cancer, 2021, 68, e29148.	1.5	10
32	Clodronate inhibits alloimmunization against distinct red blood cell alloantigens in mice. Transfusion, 2022, 62, 948-953.	1.6	10
33	Improvement in Red Blood Cell Physiology in Children with Sickle Cell Anemia Receiving Voxelotor. Blood, 2019, 134, 2281-2281.	1.4	9
34	Characterization of the severe phenotype of pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, E281.	4.1	8
35	Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome. Frontiers in Pediatrics, 2020, 8, 616731.	1.9	8
36	Hereditary xerocytosis: Diagnostic considerations. American Journal of Hematology, 2018, 93, E67-E69.	4.1	7

#	Article	IF	Citations
37	Emerging therapeutic and preventive approaches to transplant-associated thrombotic microangiopathy. Current Opinion in Hematology, 2021, Publish Ahead of Print, 408-416.	2.5	7
38	Complement Activation during Vaso-Occlusive Pain Crisis in Pediatric Sickle Cell Disease. Blood, 2021, 138, 858-858.	1.4	7
39	Congenital dyserythropoietic anaemia type I diagnosed in a young adult with a history of splenectomy in childhood for presumed haemolytic anaemia. British Journal of Haematology, 2018, 182, 10-10.	2.5	6
40	Alu element insertion inPKLRgene as a novel cause of pyruvate kinase deficiency in Middle Eastern patients. Human Mutation, 2018, 39, 389-393.	2.5	4
41	Transfusion-transmitted malaria masquerading as sickle cell crisis with multisystem organ failure. Transfusion, 2018, 58, 1550-1554.	1.6	4
42	CUTANEOUS LESIONS IN TRANSIENT ABNORMAL MYELOPOIESIS. Journal of Paediatrics and Child Health, 2012, 48, 184-185.	0.8	3
43	Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR). Blood Cells, Molecules, and Diseases, 2021, 87, 102534.	1.4	3
44	The Novel PIEZO1 Mutation p.L2023V Is Causal for Hereditary Xerocytosis Resulting in Delayed Channel Inactivation and a Dehydrated Red Blood Cell Phenotype. Blood, 2014, 124, 741-741.	1.4	3
45	Complement Mediated Hemolytic Anemia Secondary to Plasmodium ovale Infection in a Child. Journal of Pediatric Hematology/Oncology, 2019, 41, 557-558.	0.6	2
46	The Spectrum of Alpha-Spectrin Associated Hereditary Spherocytosis. Blood, 2015, 126, 941-941.	1.4	2
47	Evaluating ravulizumab for the treatment of children and adolescents with paroxysmal nocturnal hemoglobinuria. Expert Review of Hematology, 2022, , 1-8.	2.2	2
48	Co-occurrence of Chiari Malformations and Sickle Cell Diseaseâ€"A Diagnostic Dilemma. Journal of Pediatric Hematology/Oncology, 2011, 33, 624-625.	0.6	1
49	Nutritional outcomes in surgical neonates after hospital discharge. Pediatric Surgery International, 2011, 27, 553-554.	1.4	1
50	Alu-Element Insertion in Pklr Gene As a Novel Cause of Severe Hereditary Nonspherocytic Hemolytic Anemia. Blood, 2015, 126, 3349-3349.	1.4	1
51	Health Related Quality of Life and Fatigue in Patients with Pyruvate Kinase Deficiency. Blood, 2018, 132, 4807-4807.	1.4	1
52	Pyruvate Kinase (PK) Protein and Enzyme Levels in the Diagnosis and Clinical Phenotype of PK Deficiency. Blood, 2019, 134, 3515-3515.	1.4	1
53	Durability of Hemoglobin Response and Reduction in Transfusion Burden Is Maintained over Time in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat in a Long-Term Extension Study. Blood, 2021, 138, 848-848.	1.4	1
54	Variations in practice among paediatric consultants when referring unexpected neonatal deaths to a coroner. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2007, 92, F234-F234.	2.8	0

#	Article	IF	Citations
55	Evaluation and Treatment of Thrombotic Thrombocytopenic Purpura. , 2018, , 189-203.		0
56	Thrombocytosis with acquired von Willebrand disease in an adolescent with sickle cell disease. Clinical Case Reports (discontinued), 2021, 9, 457-460.	0.5	0
57	Risk of Disseminated Gonococcal Infections With Terminal Complement Blockade. Journal of Pediatric Hematology/Oncology, 2021, Publish Ahead of Print, .	0.6	0
58	Cation Leak in Red Blood Cells of Patients with Wiskott-Aldrich Syndrome Leads to Non-Immunologic Hemolysis. Blood, 2014, 124, 1338-1338.	1.4	0
59	Genotype-Phenotype Correlations in Hereditary Elliptocytosis (HE) and Hereditary Pyropoikilocytosis (HPP). Blood, 2015, 126, 3344-3344.	1.4	0
60	Reactive Oxygen Species Produced by NADPH Oxidase Contribute to Cardiac Pathology in a Mouse Model of Sickle Cell Disease. Blood, 2016, 128, 853-853.	1.4	0
61	Cellular Hydration and Oxidation As Phenotype Modifiers in Sickle Cell Anemia. Blood, 2016, 128, 2446-2446.	1.4	0
62	Primed CD4 T Cells to an Intracellular Alloantigen Facilitate Alloimmunization Following Subsequent Transfusion. Blood, 2017, 130, 768-768.	1.4	0
63	Chronic Alcohol Significantly Affects Pulmonary Function Both at Baseline and in Response to Endotoxemia. FASEB Journal, 2019, 33, 847.6.	0.5	0
64	Characterization of the Severe Phenotype of Pyruvate Kinase Deficiency. Blood, 2019, 134, 949-949.	1.4	0
65	Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency. Blood, 2019, 134, 2175-2175.	1.4	0
66	Congenital Dyserythropoietic Anemia Type I Due to Biallelic CDAN1 mutations: Report from the Congenital Dyserythropoietic Anemia Registry (CDAR). Blood, 2019, 134, 3521-3521.	1.4	0
67	6. Adolescent hematology. , 2012, , 137-170.		0
68	Sickle Cell Disease Is a Risk Factor for Transplant Associated Thrombotic Microangiopathy in Children Undergoing Hematopoietic Cellular Therapy. Transplantation and Cellular Therapy, 2022, 28, S20-S21.	1.2	0